5/22/2014 7:45:55 AM
There are several harsh lessons to be learned in drug development, and OncoGenex learned perhaps the most brutal one of all: a knockout Phase 2 trial doesn’t guarantee a thing in Phase 3. Earlier this year, Bothell, WA- and Vancouver, BC-based OncoGenex (NASDAQ: OGXI) thought it had everything figured out. Its RNA-based cancer drug, custirsen, seemed to be disarming a protein thought to help tumors resist chemotherapy. Take out that protein, and custirsen would make chemotherapy more effective. Patients should live longer. And in fact, patients in Phase 2 trials for prostate cancer on custersin and chemo lived months longer than the average for patients with similar diagnoses and chemo alone.
Help employers find you! Check out all the jobs and post your resume.
comments powered by